/ / / Profile / / /

Who we are
Founded in 1986, Ricerca Biosciences, LLC offers a unique IP-INDSM concept to pharmaceutical and biotechnology companies. Its 40+ acre site encompasses all discovery and development services required to bring intellectual property, in the form of a target or drug candidate, to a complete IND submission. The ability to perform both chemistry and biology services, as well as report writing and regulatory services, at one site makes Ricerca the provider of choice for virtual, small, and medium-sized biotech and pharmaceutical companies seeking a successful IND submission.

 

 

Drug discovery lead optimization programs

 

 

 Lead optimization programs

  • Medicinal chemistry
  • In vitro ADMET
  • In vivo ADMET
  • Metabolite ID
  • Bioavailability assessment
  • Efficacy models
  • Preformulation studies

 

Integrated drug development services
  • IND-enabling toxicology and DMPK
    • Safety pharmacology
    • Genotoxicity
  • Bioanalytical method development and sample analysis
  • Analytical services
    • Polymorph studies
    • Stability programs
    • Physical chemistry characterization
  • Process chemistry and scale-up
  • API preparation and manufacture
  • Regulatory support

 

Key personnel:
  • R. Ian Lennox, chairman
  • Jim Ault, vp quality & regulatory affairs
  • Mike Contenza, director process development & engineering
  • Mark Crane, vp business development & marketing
  • Rich Donaldson, Ph.D., vp chemical development  
  • Heidi Nelson-Keherly, Ph.D., director, client services
  • Jim Szabo, DVM, Ph.D., DACVP, vp biology services

Ricerca couples structure activity relationship (SAR) medicinal chemistry with an evaluation of a candidate's efficacy and ADMET characteristics. Once your "most likely to succeed" candidates have been identified, they are seamlessly transitioned into Ricerca's rapid preclinical drug development programs, providing integrated CMC and biology development at one site. When your drug enters human clinical investigations, Ricerca provides continued support in CMC development, late stage nonclinical toxicology and metabolism, and clinical sample analysis.